JP7511188B2 - 複合糖質ワクチン - Google Patents

複合糖質ワクチン Download PDF

Info

Publication number
JP7511188B2
JP7511188B2 JP2021510540A JP2021510540A JP7511188B2 JP 7511188 B2 JP7511188 B2 JP 7511188B2 JP 2021510540 A JP2021510540 A JP 2021510540A JP 2021510540 A JP2021510540 A JP 2021510540A JP 7511188 B2 JP7511188 B2 JP 7511188B2
Authority
JP
Japan
Prior art keywords
pneumoniae
protein
vaccine
glycoconjugate
glycoconjugates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021510540A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021526547A (ja
JP2021526547A5 (enExample
Inventor
レン，ブレンダン
ブラウン，ジェレミー
クック，ジョン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
London School of Hygiene and Tropical Medicine
Original Assignee
London School of Hygiene and Tropical Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by London School of Hygiene and Tropical Medicine filed Critical London School of Hygiene and Tropical Medicine
Publication of JP2021526547A publication Critical patent/JP2021526547A/ja
Publication of JP2021526547A5 publication Critical patent/JP2021526547A5/ja
Priority to JP2024002863A priority Critical patent/JP7833736B2/ja
Application granted granted Critical
Publication of JP7511188B2 publication Critical patent/JP7511188B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021510540A 2018-05-03 2019-05-02 複合糖質ワクチン Active JP7511188B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024002863A JP7833736B2 (ja) 2018-05-03 2024-01-11 複合糖質ワクチン

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1807303.1 2018-05-03
GBGB1807303.1A GB201807303D0 (en) 2018-05-03 2018-05-03 Glyconjugate vaccines
PCT/EP2019/061266 WO2019211386A1 (en) 2018-05-03 2019-05-02 Glyconjugate vaccines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024002863A Division JP7833736B2 (ja) 2018-05-03 2024-01-11 複合糖質ワクチン

Publications (3)

Publication Number Publication Date
JP2021526547A JP2021526547A (ja) 2021-10-07
JP2021526547A5 JP2021526547A5 (enExample) 2022-04-26
JP7511188B2 true JP7511188B2 (ja) 2024-07-05

Family

ID=62598278

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021510540A Active JP7511188B2 (ja) 2018-05-03 2019-05-02 複合糖質ワクチン
JP2024002863A Active JP7833736B2 (ja) 2018-05-03 2024-01-11 複合糖質ワクチン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024002863A Active JP7833736B2 (ja) 2018-05-03 2024-01-11 複合糖質ワクチン

Country Status (6)

Country Link
US (2) US12048743B2 (enExample)
EP (1) EP3787675A1 (enExample)
JP (2) JP7511188B2 (enExample)
CN (2) CN119454925A (enExample)
GB (1) GB201807303D0 (enExample)
WO (1) WO2019211386A1 (enExample)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006032499A1 (en) 2004-09-22 2006-03-30 Glaxosmithkline Biologicals S.A. Purification process for bacterial cytolysin
WO2017216286A1 (en) 2016-06-17 2017-12-21 Glaxosmithkline Biologicals S.A. Immunogenic composition

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
CN101983070B (zh) 2008-02-20 2016-03-30 格林考瓦因有限公司 由来源于原核细胞的重组n-糖基化蛋白制备生物共轭物
WO2010141312A2 (en) * 2009-06-01 2010-12-09 Wake Forest University Health Sciences Flagellin fusion proteins and conjugates comprising pneumococcus antigens and methods of using the same
WO2012117377A1 (en) 2011-03-02 2012-09-07 Novartis Ag Combination vaccines with lower doses of antigen and/or adjuvant
US9040057B2 (en) * 2011-09-25 2015-05-26 Chang Gung Medical Foundation, Linkou Branch Method of diagnosing and preventing pneumococcal diseases using pneumococcal neuraminidases
JP2015510872A (ja) * 2012-03-07 2015-04-13 ノバルティス アーゲー Ｓｔｒｅｐｔｏｃｏｃｃｕｓｐｎｅｕｍｏｎｉａｅ抗原の増強された製剤
GB201301085D0 (en) 2013-01-22 2013-03-06 London School Hygiene & Tropical Medicine Glycoconjugate Vaccine
US11576958B2 (en) * 2013-02-07 2023-02-14 Children's Medical Center Corporation Protein antigens that provide protection against pneumococcal colonization and/or disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006032499A1 (en) 2004-09-22 2006-03-30 Glaxosmithkline Biologicals S.A. Purification process for bacterial cytolysin
WO2017216286A1 (en) 2016-06-17 2017-12-21 Glaxosmithkline Biologicals S.A. Immunogenic composition

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Characterization of a Recombinant Pneumolysin and Its Use as a Protein Carrier for Pneumococcal Type 18C Conjugate Vaccines，INFECTION AND IMMUNITY，1995年，Vol.63, No.7，pp.2706-2713
Identification of Genes That Contribute to the Pathogenesis of Invasive Pneumococcal Disease by In Vivo Transcriptomic Analysis，Infection and Immunity，2012年，Volume 80, Number 9，pp. 3268-3278，doi:10.1128/IAI.00295-12
Immunization with components of two iron uptake ABC transporters protects mice against systemic Streptococcus pneumoniae infection，Infect Immun，2001年，69(11)，6702-6，doi: 10.1128/IAI.69.11.6702-6706.2001
Immunization with the iron uptake ABC transporter proteins PiaA and PiuA prevents respiratory infection with Streptococcus pneumoniae，Vaccine，2006年，24，pp.5133-5139，doi:10.1016/j.vaccine.2006.04.012
PiuA and PiaA, iron uptake lipoproteins of Streptococcus pneumoniae, elicit serotype independent antibody responses following human pneumococcal septicaemia，FEMS Immunology and Medical Microbiology，2005年，43，pp.73-80，doi:10.1016/j.femsim.2004.07.010
Recent developments in bacterial protein glycan coupling technology and glycoconjugate vaccine design，Journal of Medical Microbiology，2012年，61，pp.919-926，DOI 10.1099/jmm.0.039438-0
Recombinant expression of Streptococcus pneumoniae capsular polysaccharides in Escherichia coli，Open Biol，2016年，6，150243，http://dx.doi.org/10.1098/rsob.150243

Also Published As

Publication number Publication date
US20240382585A1 (en) 2024-11-21
WO2019211386A1 (en) 2019-11-07
JP2021526547A (ja) 2021-10-07
US20230241208A1 (en) 2023-08-03
JP7833736B2 (ja) 2026-03-23
US12472249B2 (en) 2025-11-18
US12048743B2 (en) 2024-07-30
EP3787675A1 (en) 2021-03-10
CN112384240B (zh) 2024-10-29
CN112384240A (zh) 2021-02-19
JP2024041903A (ja) 2024-03-27
CN119454925A (zh) 2025-02-18
GB201807303D0 (en) 2018-06-20

Similar Documents

Publication Publication Date Title
US11572391B2 (en) Antibodies for prevention, treatment and diagnosis of P. gingivalis infection
US7960535B2 (en) Recombinant lipidated PsaA protein, methods of preparation and use
JP7847091B2 (ja) 肺炎桿菌ｏ抗原ワクチン
JP2009515831A (ja) ペスト菌（Ｙｅｒｓｉｎｉａｐｅｓｔｉｓ）抗原を含む組成物
AU2019221496B2 (en) Immunogenic composition comprising staphylococcal antigens
CN101855238A (zh) 融合蛋白疫苗
JP2021528059A (ja) グリコシル化されたＣｏｍＰピリンバリアント、製造方法及びその使用
CN102488898B (zh) 龋齿疫苗及制备方法
JP7511188B2 (ja) 複合糖質ワクチン
JP2022544407A (ja) 免疫原性組成物
HK1250933A1 (en) Immunogenic fusion protein
AU2013203249A1 (en) Prevention, treatment and diagnosis of P.gingivalis infection

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210802

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220418

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220418

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230411

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230912

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240301

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240423

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240611

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240614